Peter K Vogt

List of Publications by Year in Descending Order

290 papers	25,454 citations	85 h-index	152 g-index
298 ext. papers	26,801 ext. citations	9.1 avg, IF	6.8 L-index

#	Paper	IF	Citations
290	Cryo-EM structures of PI3K reveal conformational changes during inhibition and activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
289	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. *Nature Chemistry*, **2021**, 13, 540-548	17.6	17
288	Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. *Bioorganic and Medicinal Chemistry*, **2021**, 42, 116246	3.4	1
287	An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6571-6579	11.5	16
286	A Single-Stranded DNA-Encoded Chemical Library Based on a Stereoisomeric Scaffold Enables Ligand Discovery by Modular Assembly of Building Blocks. *Advanced Science*, **2020**, 7, 2001970	13.6	13
285	From Viruses to Genes to Cells. *Annual Review of Virology*, **2019**, 6, 31-47	14.6	1
284	Cooperates with to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9. *Cancers*, **2019**, 11,	6.6	12
283	Synthetic molecules for disruption of the MYC protein-protein interface. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 4234-4239	3.4	7
282	Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 869-877	6.4	6
281	tsRNA signatures in cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 8071-8076	11.5	131
280	Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85 and p85 *Oncotarget*, **2017**, 8, 55863-55876	3.3	10
279	MINCR is not a MYC-induced lncRNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E496-7	11.5	5
278	A butterfly effect in cancer. *Molecular and Cellular Oncology*, **2016**, 3, e1029063	1.2	3
277	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. *Cell*, **2016**, 165, 643-55	56.2	188
276	Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR. *Nature Protocols*, **2015**, 10, 1198-211	18.8	67
275	MYCNOS functions as an antisense RNA regulating MYCN. *RNA Biology*, **2015**, 12, 893-9	4.8	23
274	ProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projects. *Journal of Proteomics*, **2015**, 129, 25-32	3.9	15

273	The butterfly effect in cancer: a single base mutation can remodel the cell. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 1131-6	11.5	49
272	Inhibitor of MYC identified in a Kröhnke pyridine library. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12556-61	11.5	86
271	MYC regulates the non-coding transcriptome. *Oncotarget*, **2014**, 5, 12543-54	3.3	62
270	Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K). *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 16826-9	11.5	27
269	MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. *Cancer Cell*, **2014**, 25, 469-83	24.3	235
268	In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. *Oncotarget*, **2014**, 5, 8869-78	3.3	21
267	An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e104	10.7	20
266	Retroviral oncogenes: a historical primer. *Nature Reviews Cancer*, **2012**, 12, 639-48	31.3	88
265	Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. *Cell Cycle*, **2012**, 11, 2391-401	4.7	93
264	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. *Journal of Clinical Oncology*, **2012**, 30, 457-457	2.2	2
263	PI3K p110δ more tightly controlled or constitutively active?. *Molecular Cell*, **2011**, 41, 499-501	17.6	15
262	Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. *Journal of the American Chemical Society*, **2011**, 133, 10184-94	16.4	65
261	PI3K and STAT3: a new alliance. *Cancer Discovery*, **2011**, 1, 481-6	24.4	89
260	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. *Molecular Cancer Therapeutics*, **2011**, 10, 2189-99	6.1	132
259	Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110δ of phosphoinositide-3-kinase. *Cell Cycle*, **2011**, 10, 3731-9	4.7	8
258	100 years of Rous sarcoma virus. *Journal of Experimental Medicine*, **2011**, 208, 2351-5	16.6	69
257	Essential role of Stat3 in PI3K-induced oncogenic transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13247-52	11.5	49
256	Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. *Cell Cycle*, **2011**, 10, 771-5	4.7	19

255	Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). *Cell Cycle*, **2011**, 10, 971-6	4.7	7
254	Phosphorylation of AKT: a mutational analysis. *Oncotarget*, **2011**, 2, 467-76	3.3	96
253	Smooth muscle □actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. *Oncotarget*, **2010**, 1, 9-21	3.3	11
252	Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15547-52	11.5	119
251	Oncogenes and the revolution in cancer research: homage to hidesaburo hanafusa (1929-2009). *Genes and Cancer*, **2010**, 1, 6-11	2.9	10
250	Therapeutic Targeting of Myc. *Genes and Cancer*, **2010**, 1, 650-659	2.9	116
249	Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. *Cell Cycle*, **2010**, 9, 596-600	4.7	83
248	Phosphatidylinositol 3-kinase: the oncoprotein. *Current Topics in Microbiology and Immunology*, **2010**, 347, 79-104	3.3	76
247	Long antisense non-coding RNAs and their role in transcription and oncogenesis. *Cell Cycle*, **2010**, 9, 2544-7	4.7	47
246	PI3K: from the bench to the clinic and back. *Current Topics in Microbiology and Immunology*, **2010**, 347, 1-19	3.3	57
245	Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 4299-304	11.5	48
244	Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. *International Journal of Cancer*, **2010**, 127, 239-44	7.5	14
243	Akt demoted in glioblastoma. *Science Signaling*, **2009**, 2, pe26	8.8	2
242	Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. *Molecular Pharmacology*, **2009**, 76, 491-502	4.3	47
241	Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. *Molecular Cancer Research*, **2009**, 7, 1132-8	6.6	51
240	Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. *International Journal of Cancer*, **2009**, 125, 1558-65	7.5	12
239	Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. *International Journal of Cancer*, **2009**, 125, 2863-70	7.5	305
238	Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6038-41	2.9	49

237	Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. *Journal of the American Chemical Society*, **2009**, 131, 3342-8	16.4	32
236	PI 3-kinase and cancer: changing accents. *Current Opinion in Genetics and Development*, **2009**, 19, 12-7	4.9	72
235	Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. *Journal of the American Chemical Society*, **2009**, 131, 5564-72	16.4	131
234	A humble chicken virus that changed biology and medicine. *Lancet Oncology, The*, **2009**, 10, 96	21.7	4
233	Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. *Oncogene*, **2008**, 27, 1179-82	9.2	50
232	Oncogenic signaling of class I PI3K isoforms. *Oncogene*, **2008**, 27, 2561-74	9.2	85
231	Constitutively active Rheb induces oncogenic transformation. *Oncogene*, **2008**, 27, 5729-40	9.2	50
230	Class I PI3K in oncogenic cellular transformation. *Oncogene*, **2008**, 27, 5486-96	9.2	457
229	Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike. *Cancer Cell*, **2008**, 14, 107-8	24.3	9
228	Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2652-7	11.5	328
227	Biochemical and biological characterization of tumor-associated mutations of p110alpha. *Methods in Enzymology*, **2008**, 438, 291-305	1.7	4
226	The classic: integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts: (RNA tumor viruses/reassociation kinetics/duck cells). 1973. *Clinical Orthopaedics and Related Research*, **2008**, 466, 2031-8	2.2	
225	Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. *Oncology Reports*, **2008**, 19, 825-30	3.5	25
224	A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. *Oncogene*, **2007**, 26, 3930-40	9.2	89
223	Cancer-specific mutations in phosphatidylinositol 3-kinase. *Trends in Biochemical Sciences*, **2007**, 32, 342-9	10.3	126
222	Rare cancer-specific mutations in PIK3CA show gain of function. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 5569-74	11.5	298
221	Phosphoinositide 3-kinase: from viral oncoprotein to drug target. *Virology*, **2006**, 344, 131-8	3.6	37
220	Kinase inhibitors: vice becomes virtue. *Cancer Cell*, **2006**, 9, 327-8	24.3	18

219	A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. *Journal of Cellular Physiology*, **2006**, 209, 261-5	7	22
218	PI 3-kinases: hidden potentials revealed. *Cell Cycle*, **2006**, 5, 946-9	4.7	18
217	Cancer-specific mutations in PIK3CA are oncogenic in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 1475-9	11.5	348
216	Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 12371-6	11.5	363
215	Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 1289-94	11.5	245
214	Protein Synthesis and Cancer **2006**, 180-194		
213	A credit-card library approach for disrupting protein-protein interactions. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 2660-73	3.4	73
212	Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. *Genome Research*, **2005**, 15, 1136-44	9.7	38
211	Mutated PI 3-kinases: cancer targets on a silver platter. *Cell Cycle*, **2005**, 4, 578-81	4.7	81
210	Jun: stealth, stability, and transformation. *Molecular Cell*, **2005**, 19, 432-3	17.6	9
209	Oncogenic PI3K deregulates transcription and translation. *Nature Reviews Cancer*, **2005**, 5, 921-9	31.3	622
208	Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. *Molecular and Cellular Biology*, **2005**, 25, 2095-106	4.8	74
207	Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. *Cell Cycle*, **2005**, 4, 908-13	4.7	242
206	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 802-7	11.5	688
205	Mutated PI 3-Kinases: Cancer Targets on a Silver Platter. *Cell Cycle*, **2005**, 4, 571-574	4.7	46
204	Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13613-7	11.5	174
203	Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 16204-9	11.5	62
202	An essential role for protein synthesis in oncogenic cellular transformation. *Oncogene*, **2004**, 23, 3145-50	9.2	38

201	v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. *Oncogene*, **2004**, 23, 5703-6	9.2	7
200	Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. *Journal of the American Chemical Society*, **2004**, 126, 4774-5	16.4	36
199	Genome-scale functional profiling of the mammalian AP-1 signaling pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 12153-8	11.5	94
198	Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 12384-9	11.5	58
197	Excess FoxG1 causes overgrowth of the neural tube. *Journal of Neurobiology*, **2003**, 57, 337-49		51
196	The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. *Oncogene*, **2003**, 22, 1908-15	9.2	4
195	Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. *Oncogene*, **2003**, 22, 1749-57	9.2	29
194	Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. *Oncogene*, **2003**, 22, 2151-9	9.2	27
193	MafA has strong cell transforming ability but is a weak transactivator. *Oncogene*, **2003**, 22, 7882-90	9.2	38
192	Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. *Oncogene*, **2003**, 22, 7931-41	9.2	5
191	Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. *Oncogene*, **2002**, 21, 6983-91	9.2	27
190	Fortuitous convergences: the beginnings of JUN. *Nature Reviews Cancer*, **2002**, 2, 465-9	31.3	98
189	Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 3830-5	11.5	272
188	Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. *Oncogene*, **2001**, 20, 141-6	9.2	24
187	Jun, the oncoprotein. *Oncogene*, **2001**, 20, 2365-77	9.2	249
186	Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. *Oncogene*, **2001**, 20, 4419-23	9.2	87
185	The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. *Oncogene*, **2001**, 20, 5087-92	9.2	19
184	A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 136-41	11.5	126

183	Non-Amide-Based Combinatorial Libraries Derived from N-Boc-Iminodiacetic Acid: Solution-Phase Synthesis of Piperazinone Libraries with Activity Against LEF-1/-Catenin-Mediated Transcription. *Helvetica Chimica Acta*, **2000**, 83, 1825-1845	2	24
182	Identification and characterization of genes upregulated in cells transformed by v-Jun. *Oncogene*, **2000**, 19, 3537-45	9.2	25
181	Oncogenic transformation by the FOX protein Qin requires DNA binding. *Oncogene*, **2000**, 19, 4815-21	9.2	11
180	Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. *Cellular Signalling*, **2000**, 12, 751-7	4.9	95
179	Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 1749-53	11.5	448
178	The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. *Journal of Biological Chemistry*, **2000**, 275, 6267-75	5.4	71
177	v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity. *Molecular and Cellular Biology*, **2000**, 20, 2529-42	4.8	25
176	The new serine-threonine kinase, Qik, is a target of the Qin oncogene. *Biochemical and Biophysical Research Communications*, **2000**, 276, 564-70	3.4	11
175	The oncogenic potential of the high mobility group box protein Sox3. *Cancer Research*, **2000**, 60, 6303-6	10.1	29
174	Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 139-44	11.5	158
173	Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 2077-81	11.5	223
172	Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 5716-21	11.5	79
171	The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. *Virology*, **1998**, 248, 295-304	3.6	338
170	Glutaredoxin is a direct target of oncogenic jun. *Oncogene*, **1998**, 16, 2945-8	9.2	17
169	An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14179-83	11.5	115
168	The akt kinase: molecular determinants of oncogenicity. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14950-5	11.5	249
167	Oncogenic transformation induced by the Qin protein is correlated with transcriptional repression. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 10885-8	11.5	27
166	Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 12396-400	11.5	19

165	Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. *Science*, **1997**, 276, 1848-50	33.3	372
164	Avian winged helix proteins CWH-1, CWH-2 and CWH-3 repress transcription from Qin binding sites. *Oncogene*, **1997**, 15, 483-8	9.2	29
163	Revelations of a captive: retroviral Qin and the oncogenicity of winged helix proteins. *Virology*, **1997**, 238, 1-7	3.6	18
162	Aberrant cell growth induced by avian winged helix proteins. *Cancer Research*, **1997**, 57, 123-9	10.1	22
161	Peyton Rous: homage and appraisal. *FASEB Journal*, **1996**, 10, 1559-62	0.9	8
160	Sequence-selective carbohydrate-DNA interaction: dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 940-4	11.5	53
159	The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 9805-9	11.5	91
158	Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein. *Journal of Virology*, **1996**, 70, 7161-70	6.6	56
157	Differential and antagonistic effects of v-Jun and c-Jun. *Cancer Research*, **1996**, 56, 4229-35	10.1	13
156	A quail long-term cell culture transformed by a chimeric jun oncogene. *Virology*, **1995**, 207, 321-6	3.6	15
155	The cell cycle-dependent nuclear import of v-Jun is regulated by phosphorylation of a serine adjacent to the nuclear localization signal. *Journal of Cell Biology*, **1995**, 130, 255-63	7.3	77
154	Avian cellular homolog of the qin oncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 447-51	11.5	24
153	The story of Jun. *Archives of Biochemistry and Biophysics*, **1995**, 316, 1-4	4.1	5
152	The oncogene qin codes for a transcriptional repressor. *Cancer Research*, **1995**, 55, 5540-4	10.1	48
151	The human homologue of the retroviral oncogene qin maps to chromosome 14q13. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 3616-8	11.5	6
150	Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain. *Oncogene*, **1994**, 9, 2793-7	9.2	12
149	The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 4490-4	11.5	99
148	A Jun-binding protein related to a putative tumor suppressor. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 6726-30	11.5	95

147	Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells. *Cancer Research*, **1993**, 53, 615-21	10.1	8
146	Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication. *Oncogene*, **1993**, 8, 1135-40	9.2	14
145	Nuclear translocation of viral Jun but not of cellular Jun is cell cycle dependent. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 4290-4	11.5	93
144	Mutations in the Jun delta region suggest an inverse correlation between transformation and transcriptional activation. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 618-22	11.5	47
143	Wounding acts as a tumor promoter in chickens inoculated with avian sarcoma virus 17. *Virology*, **1992**, 188, 373-7	3.6	13
142	Charles S. Mott Prize. Jun: a transcription factor becomes oncogenic. *Cancer*, **1992**, 69, 2610-4	6.4	5
141	The first family of oncogenes: appreciation of a Japanese contribution. *Japanese Journal of Cancer Research*, **1991**, 82, 1456-7		
140	jun: oncogene and transcription factor. *Advances in Cancer Research*, **1990**, 55, 1-35	5.9	256
139	Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. *Nature*, **1990**, 346, 756-60	50.4	112
138	Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. *Genes and Development*, **1990**, 4, 1677-87	12.6	155
137	The genetics of jun. *Seminars in Cancer Biology*, **1990**, 1, 27-36	12.7	3
136	The oncogene jun and nuclear signalling. *Trends in Biochemical Sciences*, **1989**, 14, 172-5	10.3	102
135	Interaction of cellular factors related to the Jun oncoprotein with the promoter of a replication-dependent hamster histone H3.2 gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 491-5	11.5	43
134	The v-sea oncogene of avian erythroblastosis retrovirus S13: another member of the protein-tyrosine kinase gene family. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 5291-5	11.5	58
133	A newly isolated avian sarcoma virus, ASV-1, carries the crk oncogene. *Oncogene*, **1989**, 4, 1281-4	9.2	35
132	v-jun encodes a nuclear protein with enhancer binding properties of AP-1. *Cell*, **1988**, 52, 705-12	56.2	195
131	Fos-associated protein p39 is the product of the jun proto-oncogene. *Science*, **1988**, 240, 1010-6	33.3	634
130	Temperature-sensitive v-sea transformed erythroblasts: a model system to study gene expression during erythroid differentiation. *Genes and Development*, **1988**, 2, 247-58	12.6	34

129	Localization of the human JUN protooncogene to chromosome region 1p31-32. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 2215-8	11.5	48
128	Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. *Science*, **1987**, 238, 1386-92	33.3	1308
127	Avian sarcoma virus 17 carries the jun oncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 2848-52	11.5	388
126	Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 3316-9	11.5	265
125	Control of erythroid differentiation: asynchronous expression of the anion transporter and the peripheral components of the membrane skeleton in AEV- and S13-transformed cells. *Journal of Cell Biology*, **1986**, 103, 1789-98	7.3	45
124	Cytoskeletal organization, vinculin-phosphorylation, and fibronectin expression in transformed fibroblasts with different cell morphologies. *Virology*, **1986**, 151, 50-65	3.6	25
123	The putative transforming protein of S13 avian erythroblastosis virus is a transmembrane glycoprotein with an associated protein kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **1985**, 82, 8237-41	11.5	38
122	Molecular cloning of the PRCII sarcoma viral genome and the chicken proto-oncogene c-fps. *Virology*, **1985**, 143, 300-8	3.6	5
121	Leukemogenicity of avian oncovirus S13. *Virology*, **1985**, 147, 466-9	3.6	
120	S13, a rapidly oncogenic replication-defective avian retrovirus. *Virology*, **1985**, 145, 141-53	3.6	32
119	Avian retrovirus S13: properties of the genome and of the transformation-specific protein. *Virology*, **1985**, 145, 154-64	3.6	26
118	An endogenous virus from Lophortyx quail is the prototype for envelope subgroup 1 of avian retroviruses. *Virology*, **1985**, 143, 595-602	3.6	5
117	Isolation of three new avian sarcoma viruses: ASV 9, ASV 17, and ASV 25. *Virology*, **1985**, 143, 680-3	3.6	41
116	Cloned DNA of defective avian sarcoma virus mutant LA46 encodes the cis-acting temperature-sensitive defect in replication. *Virology*, **1985**, 143, 684-9	3.6	1
115	Human T-cell leukemia/lymphoma viruses--an introduction. *Current Topics in Microbiology and Immunology*, **1985**, 115, 1-5	3.3	
114	ts Transformation mutants of avian sarcoma virus PRCII: lack of strict correlation between transforming ability and properties of the P105-associated kinase. *Virology*, **1983**, 125, 219-29	3.6	5
113	Class II defective avian sarcoma viruses: comparative analysis of genome structure. *Virology*, **1982**, 120, 453-64	3.6	14
112	A temperature-sensitive lesion affecting levels of transformation-specific viral RNA in a mutant of avian sarcoma virus PRCII. *Virology*, **1982**, 116, 646-9	3.6	5

111	Structural similarities of proteins encoded by three classes of avian sarcoma viruses. *Virology*, **1982**, 121, 274-87	3.6	9
110	Genome structure of the defective avian sarcoma virus PRCIV. *Virology*, **1982**, 117, 156-64	3.6	7
109	The transformation-specific proteins of avian (Fujinami and PRC-II) and feline (Synder--Theilen and Gardner--Arnstein) sarcoma viruses are immunologically related. *Virology*, **1981**, 110, 411-9	3.6	42
108	Characteristics of avian sarcoma virus strain PRCIV and comparison with strain PRCII-p. *Virology*, **1981**, 114, 451-62	3.6	22
107	The 28 S genomic RNA of avian sarcoma virus PRCII codes for the transformation-specific polyprotein P105. *Virology*, **1981**, 112, 757-61	3.6	9
106	Esh avian sarcoma virus codes for a gag-linked transformation-specific protein with an associated protein kinase activity. *Virology*, **1981**, 111, 386-400	3.6	44
105	Characterization of the transformation-specific sequences of avian erythroblastosis virus in normal vertebrate cells. *Virology*, **1981**, 111, 418-26	3.6	18
104	Avian sarcoma virus PRCII: conditional mutants temperature sensitive in the maintenance of fibroblast transformation. *Virology*, **1981**, 109, 193-7	3.6	13
103	Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII. *Virology*, **1981**, 109, 223-8	3.6	85
102	The pathogenicity and defectiveness of PRCII: a new type of avian sarcoma virus. *Virology*, **1981**, 108, 1-12	3.6	55
101	Characterization of a 105,000 molecular weight gag-related phosphoprotein from cells transformed by the defective avian sarcoma virus PRCII. *Virology*, **1981**, 108, 98-110	3.6	55
100	A third class of avian sarcoma viruses, defined by related transformation-specific proteins of Yamaguchi 73 and Esh sarcoma viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **1981**, 78, 2611-5	11.5	37
99	Cleavage of four avian sarcoma virus polyproteins with virion protease p15 removes gag sequences and yields large fragments that function as tyrosine phosphoacceptors in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **1981**, 78, 5847-51	11.5	10
98	Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73, and Fujinami viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **1981**, 78, 1906-10	11.5	24
97	Homologous tyrosine phosphorylation sites in transformation-specific gene products of distinct avian sarcoma viruses. *Nature*, **1981**, 291, 675-7	50.4	68
96	Proposal for naming host cell-derived inserts in retrovirus genomes. *Journal of Virology*, **1981**, 40, 953-7	6.6	191
95	Recovered src genes are polymorphic and contain host markers. *Virology*, **1980**, 105, 71-85	3.6	18
94	Attenuation of avian reticuloendotheliosis virus: loss of the defective transforming component during serial passage of oncogenic virus in fibroblasts. *Virology*, **1980**, 101, 304-6	3.6	8

93	The genomic RNA of avian reticuloendotheliosis virus REV. *Virology*, **1980**, 100, 450-61	3.6	33
92	Cell-free translation of avian erythroblastosis virus RNA yields two specific and distinct proteins with molecular weights of 75,000 and 40,000. *Virology*, **1980**, 100, 475-83	3.6	68
91	Genetic variation and host markers in the src gene of recovered avian sarcoma viruses. *Annals of the New York Academy of Sciences*, **1980**, 354, 384-97	6.5	2
90	PRCII, A NEW TYPE OF AVIAN SARCOMA VIRUS **1980**, 515-526		
89	Avian oncovirus MH2 is defective in Gag, Pol, and Env. *Virology*, **1979**, 92, 278-84	3.6	13
88	A nonconditional replication-defective mutant of the Schmidt-Ruppin strain of Rous sarcoma virus. *Virology*, **1979**, 92, 285-90	3.6	2
87	Avian oncovirus MH2: preferential growth in macrophages and exact size of the genome. *Virology*, **1979**, 96, 302-6	3.6	8
86	Restitution of fibroblast-transforming ability in src deletion mutants of avian sarcoma virus during animal passage. *Virology*, **1979**, 93, 413-26	3.6	40
85	Avian erythroblastosis virus: transformation-specific sequences form a contiguous segment of 3.25 kb located in the middle of the 6-kb genome. *Virology*, **1979**, 97, 366-77	3.6	72
84	Genome of avian myelocytomatosis virus MC29: analysis by heteroduplex mapping. *Proceedings of the National Academy of Sciences of the United States of America*, **1979**, 76, 1265-8	11.5	47
83	Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. *Proceedings of the National Academy of Sciences of the United States of America*, **1979**, 76, 1633-7	11.5	85
82	Integration of different sarcoma virus genomes into host DNA: evidence against tandem arrangement and for shared integration sites. *Proceedings of the National Academy of Sciences of the United States of America*, **1979**, 76, 2465-9	11.5	3
81	Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. *Cell*, **1978**, 15, 1397-410	56.2	334
80	The defectiveness of Mill Hill 2, a carcinoma-inducing avian oncovirus. *Virology*, **1978**, 89, 162-78	3.6	99
79	Ts pol mutants of avian sarcoma viruses: mapping and demonstration of single cycle recombinants. *Virology*, **1978**, 87, 21-33	3.6	9
78	Genetic analysis of the defectiveness in strain MC29 avian leukosis virus. *Virology*, **1978**, 88, 213-21	3.6	33
77	Reversion of transformed glycolysis to normal by inhibition of protein synthesis in rat kidney cells infected with temperature-sensitive mutant of Rous sarcoma virus. *Proceedings of the National Academy of Sciences of the United States of America*, **1978**, 75, 5015-9	11.5	34
76	Quantitation and localization of Rous sarcoma virus-specific RNA in transformed and revertant field vole cells. *Journal of Virology*, **1978**, 25, 518-26	6.6	17

75	Characterization of the env gene in avian oncoviruses by heteroduplex mapping. *Journal of Virology* , **1978**, 27, 667-76	6.6	24
74	Genetics of RNA Tumor Viruses **1977**, 341-455		45
73	Occurrence of partial deletion and substitution of the src gene in the RNA genome of avian sarcoma virus. *Proceedings of the National Academy of Sciences of the United States of America*, **1977** , 74, 4781-5	11.5	38
72	The RNA of avian acute leukemia virus MC29. *Proceedings of the National Academy of Sciences of the United States of America*, **1977**, 74, 4320-4	11.5	116
71	Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. *Cell*, **1977**, 11, 95-103	56.2	394
70	Properties of mammalian cells transformed by temperature-sensitive mutants of avian sarcoma virus. *Cell*, **1977**, 11, 513-21	56.2	66
69	Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. *Virology*, **1977**, 82, 431-48	3.6	265
68	The terminal oligonucleotides of avian tumor virus RNAs are genetically linked. *Virology*, **1977**, 82, 472-93	3.6	33
67	Glycolipids of chick embryo fibroblasts infected with temperature-sensitive mutants of avian sarcoma viruses. *Virology*, **1977**, 76, 485-93	3.6	35
66	Endogenous leukosis viruses in the avian family Phasianidae. *Virology*, **1977**, 76, 740-50	3.6	16
65	Phenotypic mixing between reticuloendotheliosis virus and avian sarcoma viruses. *Virology*, **1977**, 80, 127-35	3.6	22
64	Biological and biochemical studies on the inactivation of avian oncoviruses by ultraviolet irradiation. *Virology*, **1977**, 77, 689-704	3.6	18
63	Oncogenicity of avian leukosis viruses of different subgroups and of mutants of sarcoma viruses. *Infection and Immunity*, **1977**, 15, 423-8	3.7	55
62	Temperature-sensitive mutants of avian sarcoma viruses: genetic recombination between multiple or coordinate mutants and avian leukosis viruses. *Virology*, **1976**, 75, 48-59	3.6	14
61	Temperature-sensitive mutants of avian sarcoma viruses. Genetic recombination with wild type sarcoma virus and physiological analysis of multiple mutants. *Virology*, **1976**, 69, 23-34	3.6	32
60	An avian sarcoma virus mutant that is temperature sensitive for virion assembly. *Virology*, **1976**, 69, 35-49	3.6	63
59	Inhibition of avian sarcoma virus replication by glucosamine: a specific effect on the synthesis and processing of viral proteins. *Virology*, **1976**, 71, 402-11	3.6	21
58	Subgroup-specific antigenic determinants of avian RNA tumor virls structural proteins: analysis of virus recombinants. *Virology*, **1976**, 73, 372-80	3.6	29

57	Reversion from transformed to normal phenotype by inhibition of protein synthesis in rat kidney cells infected with a temperature-sensitive mutant of Rous sarcoma virus. *Proceedings of the National Academy of Sciences of the United States of America*, **1976**, 73, 3603-7	11.5	96
56	Mapping oligonucleotides of Rous sarcoma virus RNA that segregate with polymerase and group-specific antigen markers in recombinants. *Proceedings of the National Academy of Sciences of the United States of America*, **1976**, 73, 3952-6	11.5	48
55	Distribution of envelope-specific and sarcoma-specific nucleotide sequences from different parents in the RNAs of avian tumor virus recombinants. *Proceedings of the National Academy of Sciences of the United States of America*, **1976**, 73, 1073-7	11.5	47
54	DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. *Nature*, **1976**, 260, 170-3	50.4	1061
53	TOWARDS A COMPLETE GENETIC MAP OF ROUS SARCOMA VIRUS **1976**, 107-125		10
52	RNA of replication-defective strains of Rous sarcoma virus. *Proceedings of the National Academy of Sciences of the United States of America*, **1975**, 72, 1569-73	11.5	58
51	Integration of avian sarcoma virus specific DNA in mammalian chromatin. *Experimental Cell Research*, **1975**, 93, 484-6	4.2	11
50	RNA tumor virus specific sequences in nuclear DNA of several avian species. *Virology*, **1975**, 65, 524-34	3.6	53
49	Susceptibility and resistance of chicken macrophages to avian RNA tumor viruses. *Virology*, **1975**, 67, 553-65	3.6	37
48	Mapping RNase T1-resistant oligonucleotides of avian tumor virus RNAs: sarcoma-specific oligonucleotides are near the poly(A) end and oligonucleotides common to sarcoma and transformation-defective viruses are at the poly(A) end. *Journal of Virology*, **1975**, 16, 1051-70	6.6	221
47	Inhibition of avian sarcoma virus replication by glucosamine. *Virology*, **1974**, 58, 449-56	3.6	25
46	Determination of the defective function in two mutants of Rous sarcoma virus. *Virology*, **1974**, 61, 559-74	3.6	60
45	RNA tumor viruses of pheasants: characterization of avian leukosis subgroups F and G. *Virology*, **1974**, 60, 558-71	3.6	77
44	Evidence for crossing-over between avian tumor viruses based on analysis of viral RNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **1974**, 71, 4254-8	11.5	107
43	Use of Plastic Bags to Maintain a Humidified Atmosphere for Animal Cell Cultures. *Applied Microbiology*, **1974**, 27, 618-619		7
42	Proposal for numbering mutants of avian leukosis and sarcoma viruses. *Journal of Virology*, **1974**, 13, 551-4	6.6	43
41	Use of plastic bags to maintain a humidified atmosphere for animal cell cultures. *Applied Microbiology*, **1974**, 27, 618-9		1
40	ENDOGENOUS LEUKOSIS VIRUSES OF PHEASANTS **1974**, 159-171		

39	RECOMBINANTS OF AVIAN RNA TUMOR VIRUSES: CHARACTERISTICS OF THE VIRION RNA **1974**, 137-153		2
38	RNA species obtained from clonal lines of avian sarcoma and from avian leukosis virus. *Virology*, **1973**, 54, 207-19	3.6	136
37	Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. *Virology*, **1973**, 52, 535-52	3.6	240
36	Appearance of virus-specific DNA in mammalian cells following transformation by Rous sarcoma virus. *Journal of Molecular Biology*, **1973**, 74, 613-26	6.5	115
35	Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. *Proceedings of the National Academy of Sciences of the United States of America*, **1973**, 70, 3067-71	11.5	153
34	Avian tumor virus RNA: a comparison of three sarcoma viruses and their transformation-defective derivatives by oligonucleotide fingerprinting and DNA-RNA hybridization. *Proceedings of the National Academy of Sciences of the United States of America*, **1973**, 70, 2266-70	11.5	84
33	Gel electrophoresis of avian leukosis and sarcoma viral RNA in formamide: comparison with other viral and cellular RNA species. *Journal of Virology*, **1973**, 12, 594-9	6.6	203
32	Conditional lethal mutants of avian sarcoma viruses. I. Physiology of ts 75 and ts 149. *Virology*, **1971** , 43, 375-89	3.6	79
31	An avian leukosis virus related to RSV(O): properties and evidence for helper activity. *Virology*, **1971** , 43, 223-34	3.6	204
30	Conditional lethal mutants of avian sarcoma viruses. II. Analysis of the temperature-sensitive lesion in ts 75. *Virology*, **1971**, 46, 745-53	3.6	16
29	Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. *Virology*, **1971**, 46, 920-38	3.6	250
28	Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. *Virology*, **1971**, 46, 939-46	3.6	204
27	Genetically stable reassortment of markers during mixed infection with avian tumor viruses. *Virology*, **1971**, 46, 947-52	3.6	133
26	Transformation by rous sarcoma virus: effects on cellular glycolipids. *Virology*, **1971**, 44, 609-21	3.6	102
25	Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **1970**, 67, 1673-80	11.5	192
24	A mutant of rous sarcoma virus (type O) causing fusiform cell transformation. *Experimental Biology and Medicine*, **1970**, 135, 297-301	3.7	12
23	The reproductive and cell-transforming capacities of avian sarcoma virus B77: inactivation with UV light. *Virology*, **1970**, 42, 163-70	3.6	58
22	Glycoprotein components of avian and murine RNA tumor viruses. *Virology*, **1970**, 41, 631-46	3.6	165

21	Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. *Virology*, **1969**, 38, 414-26	3.6	334
20	Characteristics of two new avian tumor virus subgroups. *Virology*, **1969**, 39, 18-30	3.6	215
19	Temperature sensitive mutants of an avian sarcoma virus. *Virology*, **1969**, 39, 930-1	3.6	155
18	On the role of DNA synthesis in avian tumor virus infection. *Proceedings of the National Academy of Sciences of the United States of America*, **1969**, 64, 939-46	11.5	22
17	Effects of genetic cellular resistance on cell transformation and virus replication in chicken hematopoietic cell cultures infected with avian myeloblastosis virus (BAI-A). *Virology*, **1968**, 35, 487-97	3.6	68
16	A virus released by "nonproducing" Rous sarcoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1967**, 58, 801-8	11.5	57
15	DEAE-dextran: enhancement of cellular transformation induced by avian sarcoma viruses. *Virology*, **1967**, 33, 175-7	3.6	85
14	Phenotypic mixing in the avian tumor virus group. *Virology*, **1967**, 32, 708-17	3.6	69
13	Electron microscopy of chick fibroblasts infected by defective rous sarcoma virus and its helper. *Journal of Virology*, **1967**, 1, 400-14	6.6	29
12	Nonproducing state of Rous sarcoma cells: its contagiousness in chicken cell cultures. *Journal of Virology*, **1967**, 1, 729-37	6.6	8
11	Immunological relationships among envelope antigens of avian tumor viruses. *Virology*, **1966**, 30, 375-87	3.6	180
10	Localization of avian tumor virus group-specific antigen in cell and virus. *Virology*, **1966**, 29, 377-84	3.6	105
9	Patterns of viral interference in the avian leukosis and sarcoma complex. *Virology*, **1966**, 30, 368-74	3.6	181
8	Avian tumor viruses. *Advances in Virus Research*, **1965**, 11, 293-385	10.7	101
7	Reciprocal patterns of genetic resistance to avian tumor viruses in two lines of chickens. *Virology*, **1965**, 26, 664-72	3.6	193
6	A HETEROGENEITY OF ROUS SARCOMA VIRUS REVEALED BY SELECTIVELY RESISTANT CHICK EMBRYO CELLS. *Virology*, **1965**, 25, 237-47	3.6	83
5	Presence of avian tumor virus group-specific antigen in nonproducing Rous sarcoma cells of the chicken. *Virology*, **1965**, 27, 233-6	3.6	36
4	Observations on the surface of cells infected with Rous sarcoma virus. *Virology*, **1963**, 20, 75-87	3.6	18

3	Studies on the assay and multiplication of avian myeloblastosis virus. *Virology*, **1963**, 19, 92-104	3.6	44
2	The cytology of Rous sarcoma virus infection. *Cold Spring Harbor Symposia on Quantitative Biology*, **1962**, 27, 395-405	3.9	14
1	Localization of infectious virus and viral antigen in chick fibroblasts during successive stages of infection with Rous sarcoma virus. *Virology*, **1961**, 13, 528-44	3.6	61